NCT Number: NCT01308866
Effectiveness of a Shared Decision Aid Tool for Cardiovascular Risk Prevention in Hypercholesterolemic Patients
BACKGROUND: Mediterraneans have traditionally a low cardiovascular risk, although emerging lifestyles might change the trend. The aim of this study is to assess if hypercholesterolemic patient involvement in the preventive decision with the help of a decision aid has an impact on cardiovascular (CV) risk reduction superior to usual care.
METHOD: The design is a cluster randomised clinical trial. Participants are hypercholesterolemic patients (>200 mg/dl or c-LDL>130) from four primary care teams of Barcelona. Patients with previous CV events, age over 75 years or cognitive impairment are excluded. It is expected to create two cohorts of 139 patients each one. The randomisation is by doctor. Intervention group will receive information about their CV risk and the risk and benefits of different preventive measures. They will have access to a decission aid that will help them in the choice of the preventive measures.The material (printed and software) is adapted to the Catalan Population using local CV risk tables and will meet the CREDIBLE and DISCERN criteria. STUDY VARIABLES: Sociodemographic variables, CV risk factors, subjective health (SF 12), decisional conflict, anxiety/depression, analytic controls, treatment, treatment adherence, compliance and resources use. Basal evaluation and 3, 6, 12 month assessment. The study, financed by FIS, will begin the 01-07-2007.
RESULTS: The expected results are a higher reduction on the CV risk factors in the intervention group versus regular care.
CONCLUSIONS Study will provide a tool to be used in Spanish and Catalan population.
Looking for future studies?
Notify MeKey information
Conditions
Age range
14 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Capse-Gesclínic, Barcelona, Spain
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients between 14 and 75 years old having the inclusion criteria and consulting for cardiovascular risk diseases (CVD) in these centers.
- Patients who allow to participate in this study
Exclusion criteria
- Patients with mental disorders.
- Secundary cardiovascular risk patients
Treatment and study plan
Primary outcomes
-
Cardiovascular risk reduction
Time frame: one year
Cardiovascular risk reduction measured throught REGICOR Spanish scale
Secondary outcomes
-
Life self-perceived quality
Time frame: one year
Throught questionnaire SF-12
-
Anxiety and depression
Time frame: one year
Throught HADS scale
-
Decision empowerment
Time frame: one year
Otawa's decision scale
Sponsors and collaborators
Lead sponsor
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Other
Collaborators
- Preventive Services and Health Promotion Research Network
Registry information
Acronym: PLEGATS
Important dates
- Study start
- 2007
- Primary completion
- 2010
- Study completion
- 2011
- First posted
- Mar 4, 2011
- Registry last updated
- Mar 4, 2011
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.
NCT06423365
Cardiovascular Diseases, Dyslipidemias
Aurora, Colorado, United States
View Trial DetailsStudy of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
NCT05192941
Angina Pectoris, Arterial Occlusive Diseases
Sofia, Bulgaria
View Trial DetailsDachundou No Sugar Added Soymilk for Lipid Modulation
NCT07175766
Cardiovascular Diseases, Dyslipidemias
Taoyuan, Taiwan
View Trial DetailsA Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease
NCT05398029
Arterial Occlusive Diseases, Arteriosclerosis
Auckland, New Zealand
View Trial Details